Published in Neuroimage on April 01, 2004
Global N-acetylaspartate declines even in benign multiple sclerosis. AJNR Am J Neuroradiol (2010) 1.47
MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol (2005) 1.26
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol (2009) 1.08
MR spectroscopy indicates diffuse multiple sclerosis activity during remission. J Neurol Neurosurg Psychiatry (2009) 1.07
Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx (2005) 0.98
Analysis of the mitochondrial proteome in multiple sclerosis cortex. Biochim Biophys Acta (2011) 0.97
Global average gray and white matter N-acetylaspartate concentration in the human brain. Neuroimage (2008) 0.94
Investigating axonal damage in multiple sclerosis by diffusion tensor spectroscopy. J Neurosci (2012) 0.94
MRI pattern recognition in multiple sclerosis normal-appearing brain areas. PLoS One (2011) 0.94
(1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol (2005) 0.90
Diffuse cortical atrophy in a marmoset model of multiple sclerosis. Neurosci Lett (2008) 0.89
Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design. Comp Med (2009) 0.87
Mechanisms of neuronal damage in multiple sclerosis and its animal models: role of calcium pumps and exchangers. Biochem Soc Trans (2007) 0.84
Longitudinal whole-brain N-acetylaspartate concentration in healthy adults. AJNR Am J Neuroradiol (2011) 0.83
Whole-brain N-acetylaspartate MR spectroscopic quantification: performance comparison of metabolite versus lipid nulling. AJNR Am J Neuroradiol (2008) 0.81
Neuronal Hemoglobin Expression and Its Relevance to Multiple Sclerosis Neuropathology. J Mol Neurosci (2016) 0.80
Decreased NAA in gray matter is correlated with decreased availability of acetate in white matter in postmortem multiple sclerosis cortex. Neurochem Res (2013) 0.79
Automated whole-brain N-acetylaspartate proton MRS quantification. NMR Biomed (2014) 0.79
Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration. Eur J Radiol (2013) 0.79
Immunopathogenesis of multiple sclerosis. Ann Indian Acad Neurol (2009) 0.78
A SELDI mass spectrometry study of experimental autoimmune encephalomyelitis: sample preparation, reproducibility, and differential protein expression patterns. Proteome Sci (2013) 0.76
The neuronal metabolite NAA regulates histone H3 methylation in oligodendrocytes and myelin lipid composition. Exp Brain Res (2016) 0.76
Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment. Mult Scler (2011) 0.76
Gray Matter Atrophy Is Primarily Related to Demyelination of Lesions in Multiple Sclerosis: A Diffusion Tensor Imaging MRI Study. Front Neuroanat (2017) 0.75
Brain Parenchymal Fraction in Healthy Adults-A Systematic Review of the Literature. PLoS One (2017) 0.75
Quantifying global-brain metabolite level changes with whole-head proton MR spectroscopy at 3T. Magn Reson Imaging (2016) 0.75
Global brain metabolic quantification with whole-head proton MRS at 3 T. NMR Biomed (2017) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med (2012) 3.16
Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis. AJNR Am J Neuroradiol (2002) 2.94
Diffuse axonal injury in mild traumatic brain injury: a diffusion tensor imaging study. J Neurosurg (2005) 2.78
Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. Am J Respir Crit Care Med (2010) 2.78
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Quantitative evaluation of oxygenation in venous vessels using T2-Relaxation-Under-Spin-Tagging MRI. Magn Reson Med (2008) 2.42
Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol (2009) 2.20
Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging (2009) 2.17
A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2012) 2.13
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2012) 2.05
Mild traumatic brain injury: longitudinal regional brain volume changes. Radiology (2013) 2.05
Brain atrophy in mild or moderate traumatic brain injury: a longitudinal quantitative analysis. AJNR Am J Neuroradiol (2002) 2.02
Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol (2005) 2.01
Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology (2012) 2.00
Noninvasive quantification of whole-brain cerebral metabolic rate of oxygen (CMRO2) by MRI. Magn Reson Med (2009) 1.97
Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis. Arch Neurol (2008) 1.94
Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell (2008) 1.80
White matter damage in primary progressive aphasias: a diffusion tensor tractography study. Brain (2011) 1.73
Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology (2004) 1.72
Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage (2010) 1.71
Resting state fMRI in Alzheimer's disease: beyond the default mode network. Neurobiol Aging (2011) 1.70
Short-term DTI predictors of cognitive dysfunction in mild traumatic brain injury. Brain Inj (2008) 1.68
Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol (2002) 1.68
Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke (2006) 1.63
Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology (2012) 1.62
Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res (2010) 1.59
Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol (2003) 1.59
Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. Biol Psychiatry (2013) 1.58
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology (2012) 1.57
Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy. AJNR Am J Neuroradiol (2005) 1.56
Thalamus and cognitive impairment in mild traumatic brain injury: a diffusional kurtosis imaging study. J Neurotrauma (2011) 1.56
The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clin Exp Res (2009) 1.53
MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. Mov Disord (2010) 1.52
Language networks in semantic dementia. Brain (2009) 1.50
Weighing brain activity with the balance: Angelo Mosso's original manuscripts come to light. Brain (2013) 1.50
Brain network connectivity assessed using graph theory in frontotemporal dementia. Neurology (2013) 1.50
Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A (2009) 1.49
Cortical lesions in multiple sclerosis. Nat Rev Neurol (2010) 1.47
Motor and language DTI Fiber Tracking combined with intraoperative subcortical mapping for surgical removal of gliomas. Neuroimage (2007) 1.47
A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol (2010) 1.46
White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology (2010) 1.46
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology (2009) 1.45
Thalamic resting-state functional networks: disruption in patients with mild traumatic brain injury. Radiology (2011) 1.44
A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol (2009) 1.41
Novel approach to the measurement of absolute cerebral blood volume using vascular-space-occupancy magnetic resonance imaging. Magn Reson Med (2005) 1.41
Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol (2011) 1.40
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol (2003) 1.39
Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology (2004) 1.39
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol (2004) 1.38
Characterizing brain oxygen metabolism in patients with multiple sclerosis with T2-relaxation-under-spin-tagging MRI. J Cereb Blood Flow Metab (2012) 1.36
Optimizing the efficiency of high-field multivoxel spectroscopic imaging by multiplexing in space and time. Magn Reson Med (2006) 1.35
Disruption of white matter integrity in bipolar depression as a possible structural marker of illness. Biol Psychiatry (2011) 1.33
Age-related total gray matter and white matter changes in normal adult brain. Part II: quantitative magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol (2002) 1.33
Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol (2007) 1.32
Default-mode network disruption in mild traumatic brain injury. Radiology (2012) 1.31
A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage (2008) 1.30
Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol (2002) 1.29
Human brain-structure resolved T(2) relaxation times of proton metabolites at 3 Tesla. Magn Reson Med (2007) 1.28
Magnetic-resonance-based tracking and quantification of intravenously injected neural stem cell accumulation in the brains of mice with experimental multiple sclerosis. Stem Cells (2007) 1.27
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology (2014) 1.27
Baseline blood oxygenation modulates response amplitude: Physiologic basis for intersubject variations in functional MRI signals. Magn Reson Med (2008) 1.27
Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. J Alzheimers Dis (2010) 1.27
Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am J Neuroradiol (2005) 1.27
Incidental research imaging findings: Pandora's costly box. Neurology (2004) 1.27
Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla. J Magn Reson Imaging (2009) 1.27
Assessment of thalamic perfusion in patients with mild traumatic brain injury by true FISP arterial spin labelling MR imaging at 3T. Brain Inj (2009) 1.27
Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.26
Age-related changes in conventional, magnetization transfer, and diffusion-tensor MR imaging findings: study with whole-brain tissue histogram analysis. Radiology (2003) 1.24
Marchiafava-Bignami disease: longitudinal MR imaging and MR spectroscopy study. AJNR Am J Neuroradiol (2003) 1.23
Presurgical functional MR imaging of language and motor functions: validation with intraoperative electrocortical mapping. Radiology (2008) 1.23
What is the role of the uncinate fasciculus? Surgical removal and proper name retrieval. Brain (2010) 1.22
Comparison of the effectiveness of saturation pulses in the heart at 3T. Magn Reson Med (2008) 1.22
Optimizing the precision-per-unit-time of quantitative MR metrics: examples for T1, T2, and DTI. Magn Reson Med (2007) 1.22
Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med (2003) 1.22
Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep (2008) 1.22
Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp (2010) 1.22
Will Rogers phenomenon in multiple sclerosis. Ann Neurol (2008) 1.21